Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Expansion ⢠Strong Liquidity ⢠Leverage Concerns NVST shows improving quarterly profitability and strong cash flow/liquidity, but high leverage, intangible-asset reliance, negative retained earnings, and elevated earnings multiples warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Oversold momentum ⢠Critical support Support Level: $23.35 Resistance Level: $24.70â$25.80 NVST is in a bearish last-month downtrend with oversold rebound potential, but a break below $23.35 would raise downside risk while recovery above $24.70â$25.80 is needed to improve momentum.
Sentiment & News
Key News Insights: ⢠Institutional Buying ⢠Value Support ⢠Recent Pullback Envista remains a compelling value play with institutional buying and earnings support, though recent share weakness warrants caution.
AI Summary
NVST is becoming a cash-backed margin-recovery story, with modest sales growth expected to drive outsized EBITDA and EPS gains, but its elevated valuation leaves little tolerance for continued China and equipment-demand weakness; consider upside only if margins and free-cash-flow conversion persist while support near $23.35 holds.
Description
Envista Holdings Corp., headquartered in Brea, California, manufactures and sells a broad range of dental products and tools and employs about 12,800 full-time staff. The company operates two reporting segments: Specialty Products & Technologies, which supplies dental implant and prosthetic systems, orthodontic products and related treatment software; and Equipment & Consumables, which provides dental office equipment, imaging and visualization systems, restorative and endodontic materials, and infection-prevention supplies. Its offerings support diagnosis, treatment and routine clinical procedures across general and specialty dental practices.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 10 | Feb 17 | NVST | Envista Holdings Corp | Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty. | Closed | -7.0% |